BRAF mutations in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 54, Issue 6, 2013, Pages 1177-1182

  Jebaraj, Billy Michael Chelliah ^a   Kienle, Dirk ^b   Bühler, Andreas ^a   Winkler, Dirk ^a   Döhner, Hartmut ^a   Stilgenbauer, Stephan ^a   Zenz, Thorsten ^c,d  

^a UNIVERSITY OF ULM   (Germany)

^b Kantonspital Chur   (Switzerland)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Genetic and other predisposing conditions; Lymphoid leukemia; Pharmacotherapeutics

Indexed keywords

FLUDARABINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; SORAFENIB;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DEATH; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; EXON; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; EXONS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84877744389     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.742525     Document Type: Article

References (30)

1. Zenz T, Mertens D, Kuppers R, et al . From pathogenesis to treatment of chronic lymphocytic leukaemia . Nat Rev Cancer 2010; 10: 37- 50.
2. C hiorazzi N, R ai K R, F errarini M. C hronic lymphocytic leukemia. N Engl J Med 2005; 352: 804- 815.
3. Fabbri G, Rasi S, Rossi D, et al . Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation . J Exp Med 2011; 208 : 1389 - 1401.
4. Puente XS, Pinyol M, Quesada V, et al . Whole-genome sequencing identifi es recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475 : 101 - 105.
5. Wang L, Lawrence MS, Wan Y, et al . SF3B1 and other novel cancer genes in chronic lymphocytic leukemia . N Engl J Med 2011; 365 : 2497 - 2506.
6. Q uesada V, C onde L, V illamor N, et a l. E xome sequencing identifi es recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia Nat Genet 2011; 44: 47- 52.
7. Zhang X, Reis M, Khoriaty R, et al . Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia . Leukemia 2011; 25: 1908- 1910.
8. W eber C K, S lupsky J R, K almes H A, et a l. A ctive Ras induces heterodimerization of cRaf and BRaf . Cancer Res 2001; 61: 3595- 3598.
9. Tiacci E, Trifonov V, Schiavoni G, et al . BRAF mutations in hairy-cell leukemia . N Engl J Med 2011; 364: 2305- 2315.
10. Davies H, Bignell GR, Cox C, et al . Mutations of the BRAF gene in human cancer . Nature 2002; 417: 949- 954.
11. C ohen Y, X ing M, M ambo E, et a l. B RAF mutation in papillary thyroid carcinoma . J Natl Cancer Inst 2003; 95: 625- 627.
12. N ikiforova M N, K imura E T, G andhi M, et a l. B RAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly diff erentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399- 5404.
13. Smith ML, Snaddon J, Neat M, et al . Mutation of BRAF is uncommon in AML FAB type M1 and M2 . Leukemia 2003; 17 : 274 - 275.
14. Hou P, Liu D, Xing M . The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia 2007; 21: 2216- 2218.
15. Wan PT, Garnett MJ, Roe SM, et al . Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116 : 855 - 867.
16. Muzio M, Apollonio B, Scielzo, et al . Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: A molecular signature of anergy . Blood 2008; 112: 188- 195.
17. M essmer D, F ecteau J F, O ' H ayre M, et a l. C hronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib . Blood 2011; 117 : 882 - 889.
18. Kr o ber A, Seiler T, Benner A, et al . V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia . Blood 2002; 100: 1410- 1416.
19. D o h ner H, S tilgenbauer S, B enner A, et a l. G enomic aberrations and survival in chronic lymphocytic leukemia . N Engl J Med 2000; 343 : 1910 - 1916.
20. Willmore-Payne C, Holden JA, Hirschowitz S, et al . BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 2006; 37 : 520 - 527.
21. S o ndergaard JN, Nazarian R, Wang Q, et al . Diff erential sensitivity of melanoma cell lines with BRAFV600E mutation to the specifi c Raf inhibitor PLX4032 . J Transl Med 2010 ; 8 : 39.
22. Halaban R, Zhang W, Bacchiocchi A, et al . PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells . Pigment Cell Melanoma Res 2010; 23: 190- 200.
23. D ietrich S, G limm H, A ndrulis M, et a l. B RAF inhibition in refractory hairy-cell leukemia . N Engl J Med 2012; 366: 2038- 2040.
24. P rahallad A, S un C, H uang S, et a l. U nresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR . Nature 2012; 483 : 100 - 103.
25. Chen J, Fujii K, Zhang L, et al . Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism . Proc Natl Acad Sci USA 2001; 98 : 7783 - 7788.
26. Ping N, Wang Q, Wang Q, et al . Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia . Leuk Lymphoma 2012 Jul 9. [Epub ahead of print]
27. Langabeer SE, Quinn F, O ' Brien D, et al . Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia . Leuk Res 2012; 36: 483- 484.
28. Cucuianu A, et al . Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms . Leuk Lymphoma 2012 Apr 18. [Epub ahead of print]
29. Yang H, Higgins B, Kolinsky K, et al . RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models . Cancer Res 2010; 70: 5518- 5527.
30. Poulikakos PI, Zhang C, Bollag G, et al . RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF . Nature 2010; 464 : 427 - 430.